CN1051765C - Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine - Google Patents
Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine Download PDFInfo
- Publication number
- CN1051765C CN1051765C CN96108337A CN96108337A CN1051765C CN 1051765 C CN1051765 C CN 1051765C CN 96108337 A CN96108337 A CN 96108337A CN 96108337 A CN96108337 A CN 96108337A CN 1051765 C CN1051765 C CN 1051765C
- Authority
- CN
- China
- Prior art keywords
- compound
- hours
- amino
- column chromatography
- silica gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a heterocyclic compound with a nitrogen atom, which comprises a pentatomic ring and does not fuse with other rings. The nitrogen atom is used as a unique heterocyclic atom. (2R, 3R)-3-amino-1-1-phenyl-2-methyl pyrrolidine is a key intermediate body for synthesizing a novel antipsychotic drug of Yimobili. The heterocyclic compound uses (S)-malic acid as a raw material to start the high-stereoselectivity (larger than 95: 5) synthesis of trans-(4S, 5R)-1, 5-dialkyl-4-hydroxy-2-pyrrolidone so as to synthesize cis-(2R, 3R)-3-amino-1, 2-dibasic pyrrolidine with a pure enantiomer. The synthetic method provided by the present invention has the advantages of easy acquirement of raw materials, high yield of target products and low synthetic cost.
Description
The present invention relates to a kind of heterogeneous ring compound, contain pentatomic ring, do not condense with other ring, with a nitrogen-atoms as unique ring hetero atom.
Emonapride (Emonapride) is the little antipsychotics of developing recently of a kind of strong drug action, side effect.Its drug effect is respectively 4~73 times of present clinical medicine haloperidol commonly used (haloperidol); 408 times and 10,000 times (10 of Sulpiride (sulpiride) of Cerucal (metachloride)
4).The 3-amino of enantiomer-pure-1-benzyl-2-crassitude is the key intermediate of synthetic emonapride.Because two enantiomorphs of chiral drug often show difference even opposite physiologically active, therefore develop the megatrend that single enantiomer (also claiming enantiomer-pure) medicine has become current drug development.
(±)-emonapride
Subsequently, S.Iwanami etc. have also delivered The above results (J.Med.Chem., 24,1224-1230,1981).
Recently, day disclosure is speciallyyed permit 04 360 866,[92 360 866] (1992) disclose another kind of method by synthetic 3-amino-pyrrolidine derivatives of 3-(hydroxyl imines) pyrrolidin derivatives and analogue.Its method is in the presence of nickel borides or boronation cobalt, with sodium borohydride reduction 3-(hydroxyl imines) pyrrolidin derivatives, and synthetic 3-amino-pyrrolidine derivatives of Stereoselective and analogue.According to the catalyzer of selecting for use, suitable: reverse proportionality is not wait in 87: 13 to 94: 6.
Above-mentioned first method can only obtain suitable: the equivalent of trans isomer (1: 1) mixture, and be racemic modification; Though second method optionally obtains cis-product, what obtain is still racemic modification, is equivalent (1: the 1) mixture of levo-enantiomer and dextrorotation enantiomorph.
Purpose of the present invention be intended to develop a kind of Stereoselective synthesizing cis-(2R, 3R)-3-amino-1, the 2-disubstituted pyrrolidines and (2S, 3S)-method of single enantiomer.
Concrete synthetic route of the present invention is shown in accompanying drawing, and among narration below and the embodiment subsequently, specific synthetic product system is the numbering of middle structural formula with reference to the accompanying drawings, represents with Arabic numerals.R or S represent the absolute configuration of compound.Ph represents phenyl; Bn represents benzyl; Me represents methyl, and Ms represents methylsulfonyl.
It is feedstock production (2R, method 3R)-11 that accompanying drawing illustrates with (S)-oxysuccinic acid.
Step 4. compound 4 in tetrahydrofuran (THF) with a kind of Grignard reagent in-78 ℃~-68 ℃ down reactions 2-4 hour, dichloromethane extraction, concentrate and silica gel column chromatography after obtain compound 5 by the R definition.Said R is C
1~C
8Alkyl, benzyl or right-methoxy-benzyl, particularly methyl, benzyl and right-methoxy-benzyl; Said Grignard reagent refers to by C
1~C
8Iodo, bromo or hydrochloric ether, benzyl halide or right-methoxy-benzyl halogen, particularly methyl iodide, methyl chloride or monobromethane and the Grignard reagent made of MAGNESIUM METAL;
The dichloromethane solution of step 5. compound 5 under anhydrous titanium tetrachloride or etherate of trifluoroboron catalysis, with triethyl silicane-78 ℃ of down reduction 15~24 hours, dichloromethane extraction, concentrate and silica gel column chromatography after obtain compound 6.Trans with this method products therefrom: the ratio of cis-isomeride can obtain pure trans-isomer(ide) greater than 95: 5 after the separation.
(2R 3S)-9 reacted 30~60 hours down in 40 ℃~80 ℃ in a kind of non-proton property polar solvent with a kind of nitrogen nucleophile step 9. compound, preferably reacted 42~44 hours down at 50 ℃~60 ℃.Use extracted with diethyl ether after adding saturated aqueous common salt, concentrate with silica gel column chromatography after obtain compound (2R, 3R)-10.The compound of gained is pure cis-isomeride.Said non-proton property polar solvent is methyl-sulphoxide (DMSO) or dimethyl formamide (DMF); Said nitrogen nucleophile refers to Lithium Azide or sodiumazide.
According to the identical characteristics of different enantiomorph chemical reactivities, according to above-mentioned with (S)-oxysuccinic acid be the raw material synthetic compound (2R, method 3R)-11 and condition, from (R)-oxysuccinic acid 1, through (4R, 5S)-6 synthesized (2S, 3S)-11.Two sequences (S and R) selectivity and productive rate in steps close, have only the optically-active opposite in sign.
The present invention is a raw material from (S)-oxysuccinic acid inexpensive, that be easy to get, highly-solid selectively (>95: 5) synthesis of trans-(4S, 5R)-1,5-dialkyl group-4-hydroxyl-2-Pyrrolidone; The cis of synthetic enantiomer-pure-(2R, 3R)-3-amino-1-benzyl-2-crassitude and analogue thereof.This compound again by the antipsychotics of currently known methods one-step synthesis enantiomer-pure (2R, 3R)-emonapride.From (R)-oxysuccinic acid, synthesized another enantiomorph, that is: (2S, 3S)-3-amino-1-benzyl-2-crassitude.
Further specify the present invention with embodiment below.Embodiment 1
Get 1.5g (S)-oxysuccinic acid and 6mL Acetyl Chloride 98Min. one and arise from 50 ℃ of following stirrings 2.5 hours.Be chilled to concentrating under reduced pressure after the room temperature, a water white transparency oily thing, add the dilution of 5mL exsiccant methylene dichloride, add the dichloromethane solution 5mL that contains the 2.0mL benzylamine again, stirred 4 hours down in 40 ℃.After being chilled to room temperature, concentrating under reduced pressure gets orange-yellow transparent thick thing, adds the 6mL Acetyl Chloride 98Min. again, stirs 5 hours down in 50 ℃.Separate (ethyl acetate: sherwood oil=1: 3), get 2.35g white solid 2, productive rate 87%, m.p.64.5-65.0 ℃ with silica gel column chromatography behind the concentrating under reduced pressure.
2.35g (11.9mmol) compound 2 is dissolved in the 90mL dehydrated alcohol, drips 3.6mL (54.2mmol) Acetyl Chloride 98Min., be heated to 50 ℃ of reactions 5 hours, remove solvent under reduced pressure.Crude product removes benzene under reduced pressure with the dissolving of 6mL benzene, triplicate like this, the crude product of gained purification by silica gel column chromatography (ethyl acetate: sherwood oil=1: 1.5) get 1.83g white needle-like crystals 3, productive rate 90%, m.p.101-102 ℃.
1.83g (9.27mmol) 3 is dissolved in the 70mL ether, add 2.77mL (28.07mmol) benzyl bromine and 6.50g (28.07mmol) silver suboxide, after stirring 48 hours under 25 ℃, filter, concentrating under reduced pressure separates with silica gel column chromatography [ethyl acetate: sherwood oil=1: (5~3)], get a transparent oily matter, separate out 2.33g white solid 4 after the placement, productive rate 87%, m.p.:76-77.5 ℃.
Get 2.33g compound 4 and be dissolved in the 30mL exsiccant tetrahydrofuran (THF), be cooled to-78 ℃, under nitrogen atmosphere, add 15.8mL methyl Grignard reagent (CH
3MgI) diethyl ether solution (2.5mol/L) reacted after 4 hours, added 6mL saturated ammonium chloride solution and 100mL methylene dichloride, told organic layer; Water 70mL dichloromethane extraction three times; The organic phase anhydrous sodium sulfate drying that merges; Filter, concentrating under reduced pressure with flash chromatography method separated product (petrol ether/ethyl acetate=1: 4), obtains two isomer of 5, is white solid, is total to 1.73g, productive rate 70%.M.p.:132-133 ℃ and m.p.:131-132 ℃.
Get 1.73g (5.57mmol) 5 and be dissolved in the 20mL exsiccant methylene dichloride, under nitrogen atmosphere, be cooled to-78 ℃; Add 8.89mL (55.67mmol) triethyl silicane and 0.83mL (6.12mmol) boron trifluoride ethyl ether complex solution successively.Reaction mixture stirred 15 hours down at-78 ℃, dripped 2mL saturated sodium bicarbonate aqueous solution and 7mL water then in reaction flask, used 50mL dichloromethane extraction four times.Anhydrous sodium sulfate drying is washed, used to the organic phase that merges with the 5mL salt solution; Behind filtration, the concentrating under reduced pressure, obtain the trans product 6 of 938mg, productive rate 57% with rapid column chromatography (petrol ether/ethyl acetate=1: 4) separation.
Get 678mg (2.30mmol) compound 6 and be dissolved in the ethanol of 8mL 95%, add 244mg 10% palladium carbon catalyst, 25 ℃ were stirred 24 hours down under the 1atm nitrogen atmosphere; The reaction mixture diatomite filtration, filter residue washs three times with the 16ml ethyl acetate.Merging filtrate, concentrating under reduced pressure separates (sherwood oil: ethyl acetate=1: 2) obtain 356mg colorless oil 7, productive rate 76% with silica gel column chromatography.
The adding of the 6mL tetrahydrofuran solution of 356mg (1.73mmol) compound 7 is placed with in the exsiccant reaction flask of 455mg (12.17mmol) Lithium Aluminium Hydride.Finish, be heated to 65 ℃, stirred 3 hours with oil bath.Then, be cooled to 0 ℃, stir down and slowly splash into 0.9mL water, 0.9mL (3mmol/mL) aqueous sodium hydroxide solution and 0.9mL water successively toward reaction flask.With 90mL dichloromethane extraction four times, anhydrous sodium sulfate drying, filter, concentrating under reduced pressure, (ethyl acetate: purifying methyl alcohol=100: 2) obtains the faint yellow oily thing 8 of 303mg, productive rate 91% to crude product with silica gel column chromatography.
303mg (1.59.mmol) 8 is dissolved in the 6mL methylene dichloride, and (364mg, 3.19mmol) methylsulfonyl chloride reacted 20 hours down in 20 ℃ to add 0.3mL pyridine and 30mg4-Dimethylamino pyridine (DMAP) and 0.26ml.Add the 15mL saturated sodium bicarbonate aqueous solution behind the concentrating under reduced pressure, with 30mL dichloromethane extraction four times, the organic phase that merges is used anhydrous magnesium sulfate drying after the 3mL saturated sodium-chloride water solution is washed, use purification by silica gel column chromatography (ethyl acetate: sherwood oil=1: 2) get 262mg yellow oil 9, productive rate 61% behind the concentrating under reduced pressure.
262mg (0.97mmol) 9 and 524mg (8.05mmol) sodiumazide are dissolved in the 12mL exsiccant dimethyl formamide, under nitrogen atmosphere, reacted 28 hours in 55 ℃, add 374mg (5.61mmol) sodiumazide again, continue under identical conditions, to react 16 hours.Add the 7mL saturated aqueous common salt under the room temperature, use 20mL extracted with diethyl ether four times.The organic phase anhydrous magnesium sulfate drying that merges is used purification by silica gel column chromatography (ethyl acetate: sherwood oil=1: 7) get 153mg yellow oil 10, productive rate 73% behind filtration, the concentrating under reduced pressure.
Get 153mg (0.73mmol) 10 and be dissolved in the 4mL dry tetrahydrofuran, join at the bottom of the garden that 84mg (2.18mmol) Lithium Aluminium Hydride is housed in the flask.In nitrogen atmosphere, reacted 4 hours in 65 ℃.Then, be cooled to 0 ℃, carefully be added dropwise to 0.8mL sodium hydroxide (3mmol/mL) aqueous solution and 2mL water successively.With 20mL dichloromethane extraction five times, merge organic phase, anhydrous sodium sulfate drying filters, concentrating under reduced pressure.Crude product is through purification by silica gel column chromatography (ethyl acetate: methyl alcohol: ammoniacal liquor=100: 10: 1) get 99mg compound 11, productive rate 74%.Embodiment 2
According to the method for embodiment 1 by preparation (S)-3, (S)-2, make solvent with methyl alcohol, use by Acetyl Chloride 98Min. and the hydrogenchloride that produces as the methyl alcohol of solvent and make catalyzer, reacted 4 hours down at 60 ℃, dilute with benzene behind the concentrating under reduced pressure, concentrate the back once more and obtain compound 3, productive rate 81% with the silica gel column chromatography separation.
According to the method for embodiment 1 by preparation (S)-4, (S)-3, make solvent with tetrahydrofuran (THF), in the presence of silver suboxide, made (S)-4, productive rate 71% in 60 hours in 20 ℃ of reactions with the benzyl bromine.
Step 4, according to embodiment 1 by (S)-4 preparations (4S, method 5RS)-5 is made solvent with tetrahydrofuran (THF) ,-68 ℃ down reaction making 5, productive rate 62% in 2 hours.
Step 5, according to embodiment 1 by (4S, 5RS)-5 preparation (4S, method 5R)-6 is made catalyzer with titanium tetrachloride ,-78 ℃ down reaction made in 24 hours (4S, 5R)-6, productive rate 52%.
According to embodiment 1 by 6 preparations, 7 method, compound 6 under palladium carbon catalysis, do solvent reaction 30 hours under 15 ℃, 1atm nitrogen atmosphere with methyl alcohol, filter, concentrate and silica gel column chromatography after make 7, productive rate 65%.
According to embodiment 1 by 7 preparations, 8 method, in anhydrous diethyl ether, under 35 ℃ with Lithium Aluminium Hydride reduction 15 hours.After being cooled to 0 ℃, carefully drip entry and aqueous sodium hydroxide solution successively after, with dichloromethane extraction, concentrate and silica gel column chromatography make (2R, 3S)-8, productive rate 83%.
By 8 preparations, 9 method, compound 8 is made alkali with triethylamine and was reacted 15 hours down at 35 ℃ with benzene sulfonyl chloride in methylene dichloride according to embodiment 1.Dichloromethane extraction, concentrate and silica gel column chromatography after make (2R, 3S)-9, productive rate 56%.
Step 9, (2R, 3R)-3-azido--1-benzyl-2-crassitude (2R, 3R)-10:
According to embodiment 1 by 9 preparations, 10 method, (2R, 3S)-1-benzyl-2-methyl-3-phenylsulfonyloxy-tetramethyleneimine and Lithium Azide in dimethyl formamide (DMF), reacted 30 hours down in 80 ℃.Use extracted with diethyl ether after adding saturated aqueous common salt, concentrate with silica gel column chromatography after make (2R, 3R)-10, productive rate 61%.
According to the method for embodiment 1 by 10 preparations 11, (2R 3R)-10 in anhydrous diethyl ether, reduced 15 hours with Lithium Aluminium Hydride under 35 ℃ compound.After being cooled to 0 ℃, carefully drip entry and aqueous sodium hydroxide solution successively after, with filter, concentrate and silica gel column chromatography after make (2R, 3R)-11, productive rate 70%.Embodiment 3
According to the method for embodiment 1 by (S)-2 preparations (S)-3, with methyl alcohol make solvent, 10% tosic acid is made acid catalyst, in 40 ℃ down reaction made (S)-3 in 7 hours.
According to the method for embodiment 1 by preparation (S)-4, (S)-3, reaction made (S)-4 in 36 hours under 30 ℃.
According to embodiment 1 by (4S, 5R)-6 preparation (4S, method 5R)-7, under the 3atm nitrogen atmosphere, 32 ℃ down reaction made in 15 hours (4S, 5R)-7.
According to embodiment 1 by (2R, 3S)-8 preparation (2R, method 3S)-9,15 ℃ down reaction made in 28 hours (2R, 3S)-9.
According to embodiment 1 by (2R, 3S)-9 preparation (2R, method 3R)-10,40 ℃ down reaction made in 60 hours (2R, 3R)-10.
According to the method for embodiment 1,, make (R)-2 from (R)-oxysuccinic acid by (S)-oxysuccinic acid preparation (S)-2.2, (R)-1-benzyl-3-hydroxyl-2,5-pyrrolidine-diones (R)-(3):
According to the method for embodiment 1,, make (R)-3 from (R)-2 by preparation (S)-3, (S)-2.3, (R)-3-benzyloxy-1-benzyl-2,5-pyrrolidine-diones (R)-4:
According to the method for embodiment 1,, make (R)-4 from (R)-3 by preparation (S)-4, (S)-3.4, (4R, 5SR)-1-benzyl-4-benzyloxy-5-hydroxy-5-methyl base--2-Pyrrolidone (4R, 5SR)-5:
According to embodiment 1 by (S)-4 preparations (4S, method 5RS)-5 from (R)-4, make (4R, 5SR)-5.5, (4R, 5S)-1-benzyl-4-benzyloxy-5-N-methyl-2-2-pyrrolidone N-(4R, 5S)-6:
According to embodiment 1 by (4S, 5RS)-5 the preparation (4S, method 5R)-6, from (4R 5SR)-5 sets out, make (4R, 5S)-6.6, (4R, 5S)-1-benzyl-4-hydroxy-5-methyl base-2-Pyrrolidone (4R, 5S)-7:
According to embodiment 1 by (4S, 5R)-6 the preparation (4S, method 5R)-7, from (4R 5S)-6 sets out, make (4R, 5S)-7.7, (2S, 3R)-1-benzyl-3-hydroxy-2-methyl tetramethyleneimine (2S, 3R)-8:
According to embodiment 1 by (4S, 5R)-7 the preparation (2R, method 3S)-8, from (4R 5S)-7 sets out, make (2S, 3R)-8.8, (2S, 3R)-1-benzyl-2-methyl-3-mesyloxy-tetramethyleneimine (2S, 3R)-9:
According to embodiment 1 by (2R, 3S)-8 the preparation (2R, method 3S)-9, from (2S 3R)-8 sets out, make (2S, 3R)-9.9, (2S, 3S)-3-azido--1-benzyl-2-crassitude (2S, 3S)-10:
According to embodiment 1 by (2R, 3S)-9 the preparation (2R, method 3R)-10, (2S 3R)-9 sets out, make (2S, 3S)-10.10, (2S, 3S)-3-amino-1-benzyl-2-crassitude (2S, 3S)-11:
According to embodiment 1 by (2R, 3R)-10 the preparation (2R, method 3R)-11, by (2S 3S)-10 sets out, make (2S, 3S)-11.
Embodiment 5~8
Embodiment | RMgX | R | 5 productive rates (%) | 6 productive rates (%) |
5 | n-C 4H 9MgBr | n-C 4H 9 | 90 | 78 |
6 | i-C 4H 9MgBr | i-C 4H 9 | 71 | 78 |
7 | C 6H 5CH 2MgCl | C 6H 5CH 2 | 83 | 75 |
8 | p-CH 3OC 6H 5CH 2MgCl | p-CH 3OC 6H 5CH 2 | 89 | 83 |
Claims (8)
1. a stereoselectivity is synthesized enantiomer-pure 3-amino-1, the method for 2-disubstituted pyrrolidines, and structural formula is
, R is C
1~C
8Alkyl, benzyl or right-methoxy-benzyl is characterized in that reactions steps is as follows:
Step 1:(S)-oxysuccinic acid and Acetyl Chloride 98Min. be 40 ℃~52 ℃ reactions 2~4 hours down, dilute with methylene dichloride behind the concentrating under reduced pressure, then 30 ℃~40 ℃ down with a kind of primary amine reaction 3~5 hours, behind the concentrating under reduced pressure again with Acetyl Chloride 98Min. 40 ℃~52 ℃ down reactions 4~6 hours, concentrate after silica gel column chromatography separate compound (2)
, said primary amine is methylamine, benzylamine or right-methoxybenzylamine;
Step 2: compound (2) is made solvent with methyl alcohol or ethanol under acidic conditions, 40 ℃~60 ℃ down reactions 4~7 hours, behind the concentrating under reduced pressure with the benzene dilution, concentrate once more the back with silica gel column chromatography separate compound (3)
, the hydrogenchloride that said acidic conditions refers to direct adding hydrochloric acid or right-toluenesulphonic acids or produced by Acetyl Chloride 98Min. and alcohol as solvent;
Step 3: compound (3) in ether or tetrahydrofuran (THF), in the presence of silver suboxide with the benzyl bromine in 20 ℃~30 ℃ the reaction 36~60 hours, after the filtration compound (4)
Step 4, compound (4) in tetrahydrofuran (THF) with Grignard reagent in-78 ℃~-68 ℃ down reactions 2~4 hours, dichloromethane extraction, concentrate and silica gel column chromatography after must be by the compound (5) of R definition
Wherein the definition of R is the same, and said Grignard reagent is by C
1-C
8Iodo, bromo or hydrochloric ether, benzyl halide or right-methoxy-benzyl halogen and the Grignard reagent made of MAGNESIUM METAL;
The dichloromethane solution of step 5, compound (5) under anhydrous titanium tetrachloride or etherate of trifluoroboron catalysis, with triethyl silicane-78 ℃ of down reduction 15~24 hours, dichloromethane extraction, concentrate and silica gel column chromatography after compound (6)
, wherein the definition of R is the same;
Step 6: compound (6) under palladium carbon catalysis, in methyl alcohol or ethanol, the nitrogen atmosphere of 1~3atm and 15 ℃~32 ℃ reaction 15~30 hours down, filter, concentrate and silica gel column chromatography after obtain compound (7)
, wherein the definition of R is the same;
Step 7: compound (7) and Lithium Aluminium Hydride in ether or tetrahydrofuran (THF), 35 ℃~67 ℃ reactions 2~15 hours down, add entry and aqueous sodium hydroxide solution successively after, with dichloromethane extraction, concentrate and silica gel column chromatography after, obtain compound (8)
, wherein the definition of R is the same;
Step 8: compound (8) is in methylene dichloride, in the presence of a kind of alkali and esterifying catalyst 4-Dimethylamino pyridine with a kind of SULPHURYL CHLORIDE in 15 ℃~35 ℃ down reactions 15~28 hours, dichloromethane extraction, concentrate and silica gel column chromatography after must be by the compound (9) of R and X definition
, wherein the definition of R is the same, and said SULPHURYL CHLORIDE is p-toluenesulfonyl chloride, benzene sulfonyl chloride or methylsulfonyl chloride, and X is ptoluene-sulfonyl, benzenesulfonyl, methylsulfonyl, and said alkali is tertiary amine;
Step 9: compound (9) and Lithium Azide or sodiumazide in 40 ℃~80 ℃ reactions 30~60 hours down, use extracted with diethyl ether after adding saturated aqueous common salt in dimethyl formamide, concentrate with silica gel column chromatography after obtain compound (10)
, wherein the definition of R is the same;
Step 10: compound (10) in ether or tetrahydrofuran (THF), under 35 ℃~67 ℃ with Lithium Aluminium Hydride reduction 3~15 hours, add entry and aqueous sodium hydroxide solution successively after, after filtration, concentrate and silica gel column chromatography after obtain target compound (11)
, wherein the definition of R is the same.
2. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1, and the method for 2-disubstituted pyrrolidines is characterized in that the primary amine described in the step 1 is a benzylamine.
3. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1, the method for 2-disubstituted pyrrolidines, and the reaction conditions that it is characterized in that step 2 is 45 ℃~55 ℃ and reacted 5~6 hours down.
4. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1, and the method for 2-disubstituted pyrrolidines is characterized in that the Grignard reagent described in the step 5 is the Grignard reagent that methyl iodide or methyl chloride or monobromethane and MAGNESIUM METAL are made; And the R in the compound (5) is a methyl.
5. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1, the method for 2-disubstituted pyrrolidines, and the reaction conditions that it is characterized in that step 6 is 1atm nitrogen atmosphere, 20 ℃~25 ℃ following reactions 24 hours.
6. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1, and the method for 2-disubstituted pyrrolidines is characterized in that the reaction conditions in the step 7 is in tetrahydrofuran (THF), and 65 ℃ were reacted 3 hours down.
7. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1; the method of 2-disubstituted pyrrolidines; it is characterized in that the alkali described in the step 8 is pyridine or triethylamine, said SULPHURYL CHLORIDE is a methylsulfonyl chloride, and the X in the compound (9) is a methylsulfonyl.
8. a kind of stereoselectivity as claimed in claim 1 is synthesized enantiomer-pure 3-amino-1, the method for 2-disubstituted pyrrolidines, and the reaction conditions that it is characterized in that step 9 is for reacting 42~44 hours down at 50 ℃~60 ℃; Compound in the step 10 (10) is in tetrahydrofuran (THF), and 65 ℃ were reacted 4 hours down.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96108337A CN1051765C (en) | 1996-06-25 | 1996-06-25 | Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96108337A CN1051765C (en) | 1996-06-25 | 1996-06-25 | Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1143635A CN1143635A (en) | 1997-02-26 |
CN1051765C true CN1051765C (en) | 2000-04-26 |
Family
ID=5119936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96108337A Expired - Fee Related CN1051765C (en) | 1996-06-25 | 1996-06-25 | Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1051765C (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104211630B (en) * | 2013-05-30 | 2016-05-04 | 福州大学 | A kind of alkaloid compound and application thereof that comes from tangerine green trichoderma |
RU2016131875A (en) * | 2014-01-20 | 2018-02-26 | Ф. Хоффманн-Ля Рош Аг | N-Phenyllactam derivatives capable of stimulating neurogenesis and their use in the treatment of diseases of the nerve system |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210660A (en) * | 1978-12-20 | 1980-07-01 | Yamanouchi Pharmaceutical Co., Ltd. | Benzamide derivatives |
DE2855853A1 (en) * | 1978-12-22 | 1980-07-10 | Yamanouchi Pharma Co Ltd | N-(3-Pyrrolidine)-substd. benzamide derivs. - have CNS depressant activity, providing use as psychotropic drugs |
GB2037740A (en) * | 1978-12-21 | 1980-07-16 | Yamanouchi Pharma Co Ltd | Benzamide derivatives |
JPH04360866A (en) * | 1991-06-06 | 1992-12-14 | Sankyo Kagaku Kk | Production of 3-aminopyrrolidines |
-
1996
- 1996-06-25 CN CN96108337A patent/CN1051765C/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210660A (en) * | 1978-12-20 | 1980-07-01 | Yamanouchi Pharmaceutical Co., Ltd. | Benzamide derivatives |
GB2037740A (en) * | 1978-12-21 | 1980-07-16 | Yamanouchi Pharma Co Ltd | Benzamide derivatives |
DE2855853A1 (en) * | 1978-12-22 | 1980-07-10 | Yamanouchi Pharma Co Ltd | N-(3-Pyrrolidine)-substd. benzamide derivs. - have CNS depressant activity, providing use as psychotropic drugs |
JPH04360866A (en) * | 1991-06-06 | 1992-12-14 | Sankyo Kagaku Kk | Production of 3-aminopyrrolidines |
Also Published As
Publication number | Publication date |
---|---|
CN1143635A (en) | 1997-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morton et al. | Chiral non-racemic sulfinimines: versatile reagents for asymmetric synthesis | |
Narasaka et al. | Asymmetric Diels-Alder reaction catalyzed by a chiral titanium reagent | |
Burnett | Asymmetric synthesis and absolute stereochemistry of cholesterol absorption inhibitor, SCH 48461 | |
CN1051765C (en) | Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine | |
CN1121381C (en) | Novel process for preparing ketimine | |
JP4564010B2 (en) | Process for producing optically active aziridine compound and amine compound, and complex and intermediate used in the process | |
CN1051764C (en) | Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine | |
IL193154A (en) | Method of producing optically active alcohol | |
CN1142130C (en) | Process for manufacture of trans-(R,R)-actinol | |
CN102126954A (en) | New synthesis method of optically pure lactone | |
CN1834093A (en) | Synthesis method of chiral 2-amino-1- (6-fluoro-3, 4-dihydrobenzopyranyl) ethanol | |
CN1161353C (en) | Process for production of paroxetine | |
CN1189458C (en) | Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine | |
Bergmeier et al. | Three-membered ring systems | |
CN1785960A (en) | Preparation method of alpha-alkyl-isoserine and byproduct | |
CN1220686C (en) | Beta-hydroxy-alpha-amino acid and its derivatives and synthesizing method for preparing template | |
CN1310886C (en) | Phenol derivatives and method of use thereof | |
US8846944B2 (en) | Regeneration of 2,2′-cyclopropylidene-bis (oxazolines) | |
CN1385409A (en) | Optical resolution method for recemic diphenol | |
CN1176924C (en) | Chirality catalyst for oxidative coupling naphthol | |
Birk et al. | With asymmetric hydrogenation towards a new, enantioselective synthesis of orlistat | |
Kunieda et al. | Synthetic versatility of 2-oxazolone heterocycle for stereo-controlled construction of 2-amino alcohols | |
CN101037457A (en) | Branched polyhydroxy pyrrole derivatives and preparation method and application | |
CN1616385A (en) | Enantiomerically enriched 2-butanol | |
WO2015063791A1 (en) | Novel process for total synthesis of venlafaxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |